EUCTR2010-018849-59-DE进行中（未招募）1 期
A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer - PROVE
GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH0 个研究点开始时间: 2011年1月5日最近更新:
适应症
相关药物
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Female patients with pretreated epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer with histological confirmation of the tumor
- •Wild-type k-ras status
- •Patients must have pretreated platinum-sensitive ovarian cancer with recurrence more than 6 months after completion of a platinum-containing regimen
- •Presence of at least one measurable or non-measurable disease (e.g. malignant ascites) following RECIST criteria by radiologic evaluation OR histological confirmation of recurrence by biopsy. The presence of non-measurable lesions only requires in addition a 2-fold increase of CA-125 elevation above normal lab value (confirmed by two measurements).
- •No more than 2 prior treatment regimens for these epithelial cancers
- •Age = 18 years
- •ECOG Performance Status of 0 or 1
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •- Hemoglobin > 9.0 g/dl
- •- Leukocyte count >3.000/mm3 ; absolute neutrophil count (ANC) >1.500/mm3
- •- Platelet count ? 100.000/µl
- •- Total bilirubin < 1,0 times the upper limit of normal
- •- ALT and AST < 2,5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer)
- •- Alkaline phosphatase < 4 x ULN
- •- PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.]
- •- Serum creatinine < 1.5 x upper limit of normal and creatinine clearance > 50 ml/min.
- •- Magnesium = lower limit of normal; calcium = lower limit of normal
- •Signed and dated informed consent before the start of specific protocol procedures.(Analysis of K-RAS mutation status)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = 1 year before enrolment.
- •History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- •History of HIV infection or chronic hepatitis B or C
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •Pre-existing neuropathy > grade 1 (NCI CTCAE), except for loss of tendon reflex
- •Prior radiological or clinical evidence of CNS metastases including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement by head CT scan or MRI
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •History of organ allograft
- •Patients with evidence or history of bleeding diathesis
- •Patients undergoing renal dialysis
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •Patients in a closed institution according to an authority or court decision
- •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- •Excluded therapies and medications, previous and concomitant:
- •Anticancer chemotherapy within 4 weeks prior to study entry.
- •Prior anti-EGFR therapy
- •Radiotherapy during study or within 4 weeks of start of study drug. (Palliative radiotherapy of non-target lesions will be allowed) and prior radiotherapy of > 25% of the bone marrow
- •Major surgery within 4 weeks of start of study
- •Autologous bone marrow transplant or stem cell rescue within 12 months of study
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results
研究者
相似试验
进行中（未招募）
不适用
A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer.Ensayo piloto randomizado en fase II que compara carboplatino y docetaxel en pacientes con cáncer de mama genético metastásico. - BRCA TrialEUCTR2004-001496-20-ESniversity College London
进行中（未招募）
不适用
Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer.endometrial cancerMedDRA version: 14.1Level: LLTClassification code 10014770Term: Endometrioid adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003301-16-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI108
进行中（未招募）
1 期
A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination .Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.MedDRA version: 20.0Level: LLTClassification code 10006888Term: Ca ovarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10061269Term: Malignant peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002860-42-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE234
已完成
不适用
Randomized phase II trial comparing carboplatin plus irinotecan with carboplatin plus amrubicine for extensive disease small-cell lung cancerSmall-cell lung cancerJPRN-UMIN000008970orth-Japan lung cancer group70
进行中（未招募）
1 期
A trial of carboplatin and gemcitabine +/- vandetanib to treat patients with advanced bladder cancer who can't be treated with cisplatiTransitional cell carcinoma of urothelium (upper or lower urinary tract). Cancers with other pathologies are permitted, provided that the dominant morphology is transitional cell carcinoma.EUCTR2009-010140-33-GBCardiff University82